Sarepta Therapeutics
Sarepta Therapeutics, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). Founded in 1980, Sarepta has achieved significant milestones, including the development of its pioneering exon-skipping therapies, which offer unique treatment options for patients with DMD. With a strong focus on advancing precision medicine, Sarepta's core products, such as eteplirsen and golodirsen, utilise cutting-edge technology to address the underlying genetic causes of muscular dystrophies. The company has established a prominent market position, recognised for its commitment to transforming the lives of patients through groundbreaking therapies. As it continues to expand its operational reach, Sarepta remains dedicated to innovation and excellence in the biotechnology industry.
DitchCarbon Score
How does Sarepta Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sarepta Therapeutics's score of 26 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sarepta Therapeutics's reported carbon emissions
In 2023, Sarepta Therapeutics reported total carbon emissions of approximately 4,789,000 kg CO2e from Scope 1 and 2 sources. This represents a reduction from 2022, where emissions were about 5,000,000 kg CO2e. Specifically, Scope 1 emissions decreased to about 4,789,000 kg CO2e in 2023 from 5,000,000 kg CO2e in 2022, while Scope 2 emissions also saw a decline from approximately 3,428,000 kg CO2e in 2022 to about 2,701,000 kg CO2e in 2023. Sarepta has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The company continues to focus on reducing its carbon footprint through operational efficiencies, as indicated by the decrease in emissions per employee, which fell from 250 kg CO2e in 2022 to 230 kg CO2e in 2023. Overall, Sarepta Therapeutics is making strides in reducing its carbon emissions, aligning with industry standards for sustainability, although further commitments and targets would enhance their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 5,000,000 | 0,000,000 |
| Scope 2 | 3,428,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sarepta Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
